Smithsonian Magazine Investigates Peptide Industry’s Regulatory Gaps
Smithsonian Magazine examines how peptides like BPC-157 and TB-500 grew into a parallel healthcare system outside FDA oversight, highlighting regulatory gaps and consumer risks.
Category Regulation
FDA Adverse Event Reports for Compounded GLP-1s Top 1,700
FDA logs over 1,700 adverse event reports for compounded GLP-1s as a JAMA study finds compounders altering formulations to dodge the agency's copying ban.
Washington Post Exposes Financial Forces Driving GLP-1 Prescribing
A Washington Post investigation reveals firms are spending hundreds of millions to influence doctors' GLP-1 prescribing decisions across the United States.
Fifth Circuit Upholds FDA, Restricting Compounded GLP-1 Supply
The Fifth Circuit upheld FDA's shortage determination for semaglutide and tirzepatide, locking in restrictions on compounded GLP-1 supply and reducing patient access.
BBC Investigation Exposes Gray-Market Retatrutide Supply Chain
BBC News investigates how consumer demand for Eli Lilly's investigational retatrutide is fueling counterfeit sales through unregulated channels ahead of FDA filing.
FDA Warns Five Peptide Vendors as September 8 Response Deadline Nears
FDA warning letters dated August 24 target five online peptide vendors selling unapproved retatrutide and other peptides. A September 8 response deadline approaches.
FDA Updates GLP-1 Compounding Guidance, Flags Fraudulent Labels
FDA guidance documents compounded GLP-1 drugs arriving warm and vials labeled with nonexistent pharmacies, while an existing import alert continues targeting substandard ingredients.
FDA Tracks 990 Adverse Events From Compounded GLP-1s
FDA has received 990 adverse-event reports tied to compounded semaglutide and 730+ from compounded tirzepatide as of May 2026, with dosing errors among the problems cited.
FDA Warning Letter Deadline for Five Peptide Vendors Expires September 8
Five online peptide vendors face a September 8 deadline to respond to FDA warning letters citing unapproved drug sales including semaglutide and tirzepatide.
FDA Warning Letters Target Five Online Peptide Vendors
FDA issued warning letters to five online peptide sellers for unapproved GLP-1 drugs, with responses due within 15 working days of receipt.
